Literature DB >> 24380095

Quantifying the benefits and harms of screening mammography.

H Gilbert Welch1, Honor J Passow1.   

Abstract

Like all early detection strategies, screening mammography involves trade-offs. If women are to truly participate in the decision of whether or not to be screened, they need some quantification of its benefits and harms. Providing such information is a challenging task, however, given the uncertainty--and underlying professional disagreement--about the data. In this article, we attempt to bound this uncertainty by providing a range of estimates-optimistic and pessimistic--on the absolute frequency of 3 outcomes important to the mammography decision: breast cancer deaths avoided, false alarms, and overdiagnosis. Among 1000 US women aged 50 years who are screened annually for a decade, 0.3 to 3.2 will avoid a breast cancer death, 490 to 670 will have at least 1 false alarm, and 3 to 14 will be overdiagnosed and treated needlessly. We hope that these ranges help women to make a decision: either to feel comfortable about their decision to pursue screening or to feel equally comfortable about their decision not to pursue screening. For the remainder, we hope it helps start a conversation about where additional precision is most needed.

Entities:  

Mesh:

Year:  2014        PMID: 24380095     DOI: 10.1001/jamainternmed.2013.13635

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  61 in total

1.  Perspective: The risks of overdiagnosis.

Authors:  Alexandra Barratt
Journal:  Nature       Date:  2015-11-19       Impact factor: 49.962

Review 2.  Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Authors:  Sudhir Srivastava; Brian J Reid; Sharmistha Ghosh; Barnett S Kramer
Journal:  J Cell Physiol       Date:  2016-04-29       Impact factor: 6.384

3.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

4.  Medicalization and overdiagnosis: different but alike.

Authors:  Bjørn Hofmann
Journal:  Med Health Care Philos       Date:  2016-06

5.  Psychological impact of breast cancer screening in Japan.

Authors:  Atsuko Kitano; Hideko Yamauchi; Takashi Hosaka; Hiroshi Yagata; Keiko Hosokawa; Sachiko Ohde; Seigo Nakamura; Masafumi Takimoto; Hiroko Tsunoda
Journal:  Int J Clin Oncol       Date:  2015-05-26       Impact factor: 3.402

Review 6.  Breast cancer screening: an evidence-based update.

Authors:  Mackenzie S Fuller; Christoph I Lee; Joann G Elmore
Journal:  Med Clin North Am       Date:  2015-03-05       Impact factor: 5.456

Review 7.  Imaging-based screening: maximizing benefits and minimizing harms.

Authors:  Jessica C Germino; Joann G Elmore; Ruth C Carlos; Christoph I Lee
Journal:  Clin Imaging       Date:  2015-06-12       Impact factor: 1.605

8.  Risk, Overdiagnosis and Ethical Justifications.

Authors:  Wendy A Rogers; Vikki A Entwistle; Stacy M Carter
Journal:  Health Care Anal       Date:  2019-12

9.  Quality of the screening process: An overlooked critical factor and an essential component of shared decision making about screening.

Authors:  James A Dickinson; Roland Grad; Brenda J Wilson; Neil R Bell; Harminder Singh; Olga Szafran; Guylène Thériault
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

10. 

Authors:  James A Dickinson; Roland Grad; Brenda J Wilson; Neil R Bell; Harminder Singh; Olga Szafran; Guylène Thériault
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.